Text
Clinical Trial on the Efficacy of Sandostatin Compared to Pituitary Extract toward Melenial Hematemesis Caused by Variceal Haemorrhage (Uji Klinis Effektivitas Pemberian Sandostatin pada Penderita Hematemesis Melena Akibat Pecahnya Varises Esofagus Dibandingkan dengan Pemberian Ekstrak Pituitary)
Fifty patients entered into a prospective clinical trial comparing the efficacy of sandostatin, and pituitary extract in controlling acute variceal haemorrhage. All patients were hospitalized in Hasan Sadikin and St. Borromeus Hospital, Bandung from March until December 1993. Endoscopic were performed to confirmed the diagnosis before medical treatment. Group I, 25 patients were treated with pituitary extract. There were 4 females and 21 males. The youngest 24 and the oldest 64 years, with a mean age of 53.1 years old. Group II, 25 patients were treated with sandostatin. There were 6 females and 19 males. The youngest 24 and the oldest 74 years with a mean age of 57.1 years old. The average dose of pituitary extract was 20 ampules and in sandostatin 5 ampules. Bleeding stopped in 9 patients (36.0 percent) of patients treated with pituitary extract, and in 18 patients (72.0 percent) treated with sandostatin. The mortality rate in 10 patients (40.0 percent) in group I, and in 5 patients (20.0 percent), in group II rebleeding occured in 9 patients after 8-32 hours treated with sandostatin. According to above data, it is concluded that sandostatin was significantly more succesful in controlling acute variceal haemorrhage than pituitary extract. Besides, no side effects were observed during treatment with sandostatin.
No other version available